GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxil Bio Ltd (TSXV:VXL) » Definitions » Gross-Profit-to-Asset %

Vaxil Bio (TSXV:VXL) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Vaxil Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Vaxil Bio's annualized Gross Profit for the quarter that ended in Dec. 2023 was C$0.00 Mil. Vaxil Bio's average Total Assets over the quarter that ended in Dec. 2023 was C$1.01 Mil. Therefore, Vaxil Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


Vaxil Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Vaxil Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxil Bio Gross-Profit-to-Asset % Chart

Vaxil Bio Annual Data
Trend May14 May15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vaxil Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vaxil Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Vaxil Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxil Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's Gross-Profit-to-Asset % falls into.



Vaxil Bio Gross-Profit-to-Asset % Calculation

Vaxil Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (1.541+0.976)/ 2 )
=0/1.2585
=0.00 %

Vaxil Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (1.05+0.976)/ 2 )
=0/1.013
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Vaxil Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Vaxil Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxil Bio (TSXV:VXL) Business Description

Traded in Other Exchanges
Address
C/O Kira Lynn, Bennet Jones LLP, 3400 One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.

Vaxil Bio (TSXV:VXL) Headlines

No Headlines